Davy James, Managing Editor

Liver disease experts suggest how to prioritize the treatment of different HCV patient groups.

Keytruda has already been approved for metastatic non-small cell lung cancer and metastatic melanoma.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

There are currently no approved treatments for tenosynovial giant cell tumors.

Cancer microenvironment may hold the key to increasing immunotherapy drug efficacy.

With the high volume of cancer drugs available, determining the most effective combination is a significant hurdle.

Risk of death in patients with cardiovascular and respiratory conditions amplified in female patients with rheumatoid arthritis.

Multiple myeloma therapeutic spending forecast to his $22.4 billion by 2023.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses methods to overcome the challenge of high out-of-pocket costs that can have a negative impact on patient medication adherence.

Research shows cells are unable to divide and invade at the same time.

Top stories of the week on Specialty Pharmacy Times.

Ligand-guided protein cages kill more than 70 percent of lung cancer cells during testing.

T-VEC is a first-in-class immunotherapy for unresectable cutaneous, subcutaneous, and nodal lesions in advanced melanoma.

Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses the services offered by Diplomat's HUB EnvoyHealth program.

Mischaracterization of specialty pharmacy rampant amid growing controversy regarding specialty drug pricing.

Tom Roark, PAHM, director of contract management at Diplomat, discusses the value contract management in specialty pharmacy operations.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses how technology can be utilized to improve patient outcomes.

Veltassa binds with potassium in the gastrointestinal tract to reduce absorption.

Atheer Kaddis, PharmD, senior vice president of Business Development and Sales at Diplomat, discusses services offered by Diplomat's Hospital Specialty Program.

Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.

Top stories of the week on Specialty Pharmacy Times.

Jay Greco, RPh, owner of Jersey Shore Pharmacy, discusses significant issues causing difficulties for specialty pharmacy.

Just 5% of myeloma cases are in the first phase at diagnosis.

Marc O'Connor, chief operating officer of Curant Health, discusses methods Curant uses to maintain adherence to specialty drug regimens.

Top stories of the week on Specialty Pharmacy Times.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the growth of the annual NASP Specialty Pharmacy Conference, held from Sept. 29 through Oct. 1, 2015.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses the difficulties pharmacies face regarding clinical support for patients starting specialty therapies.

Joseph Morse, president and chief operating officer of Therigy, LLC, discusses significant challenges in over the next five years in specialty pharmacy.

Top stories of the week on Specialty Pharmacy Times.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how accountable care organizations impact specialty pharmacy.